In this episode, I discuss corneal disease and treatments with David Eveleth, PhD, the founder, president and CEO of Trefoil Therapeutics. Brought to you by Alcon ·       Welcome to another exciting episode of Eye Care insider :14 ·       Intro David Eveleth, PhD :47 ·       Eveleth’s background 1:05 ·       What’s the treatment landscape now for corneal diseases and where are we falling short for patients? 2:59 ·       The origins of Trefoil Therapeutics 7:27 ·       FGF-1: Is it just important in the endothelium or is it also important in the epithelium? 11:47 ·       What is your current lead investigational candidate? 14:01 ·       When do you expect another read out of clinical data? 21:47 ·       An adjunctive therapy with cataract surgery 18:27 ·       What is the timeline of administration to patients? 19:24 ·       When do you expect a readout of clinical data? 20:49 ·       Is it possible to use this also for the epithelium? 21:39 ·       What are the most important challenges facing the ophthalmic industry? What is the most important factor to look for? 24:07 ·       For more information about David Eveleth, PhD, and Trefoil Therapeutics, visit <a href= "http://www.trefoiltherapeutics.com">www.trefoiltherapeutics.com</a> 25:53 ·       Corneal disease can be fixed and better vision is possible 26:44 ·       Thanks for listening 27:04 We’d love to hear from you! Send your comments/questions to Dr. Mali at <a href= "mailto:eyecareinsider@healio.com">eyecareinsider@healio.com</a>. Follow us on Twitter <a href= "https://twitter.com/HRheuminations">@Healio_OSN</a>. You can find follow Trefoil Therapeutics on Twitter @TrefoilThera. David Eveleth, PhD, is the president and CEO of Trefoil Therapeutics. Disclosures: Eveleth is the founder, CEO and shareholder of Trefoil Therapeutics. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI.

<description>&lt;p class="MsoNormal"&gt;In this episode, I discuss corneal disease and treatments with &lt;strong&gt;David Eveleth, PhD,&lt;/strong&gt; the founder, president and CEO of Trefoil Therapeutics.&lt;/p&gt; &lt;p class="MsoNormal"&gt;&lt;em&gt;Brought to you by Alcon&lt;/em&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpFirst" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Welcome to another exciting episode of Eye Care insider &lt;strong&gt;&lt;em&gt;:14&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Intro David Eveleth, PhD &lt;strong&gt;&lt;em&gt;:47&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Eveleth’s background &lt;strong&gt;&lt;em&gt;1:05&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;What’s the treatment landscape now for corneal diseases and where are we falling short for patients? &lt;strong&gt;&lt;em&gt;2:59&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;The origins of Trefoil Therapeutics &lt;strong&gt;&lt;em&gt;7:27&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;FGF-1: Is it just important in the endothelium or is it also important in the epithelium? &lt;strong&gt;&lt;em&gt;11:47&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;What is your current lead investigational candidate? &lt;strong&gt;&lt;em&gt;14:01&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;When do you expect another read out of clinical data? &lt;strong&gt;&lt;em&gt;21:47&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;An adjunctive therapy with cataract surgery &lt;strong&gt;&lt;em&gt;18:27&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;What is the timeline of administration to patients? &lt;strong&gt;&lt;em&gt;19:24&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;When do you expect a readout of clinical data? &lt;strong&gt;&lt;em&gt;20:49&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Is it possible to use this also for the epithelium? &lt;strong&gt;&lt;em&gt;21:39&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;What are the most important challenges facing the ophthalmic industry? What is the most important factor to look for? &lt;strong&gt;&lt;em&gt;24:07&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;For more information about David Eveleth, PhD, and Trefoil Therapeutics, visit &lt;a href= "http://www.trefoiltherapeutics.com"&gt;www.trefoiltherapeutics.com&lt;/a&gt; &lt;strong&gt;&lt;em&gt;25:53&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Corneal disease can be fixed and better vision is possible &lt;strong&gt;&lt;em&gt;26:44&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpLast" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Thanks for listening &lt;strong&gt;&lt;em&gt;27:04&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoNormal"&gt;We’d love to hear from you! Send your comments/questions to Dr. Mali at &lt;a href= "mailto:eyecareinsider@healio.com"&gt;eyecareinsider@healio.com&lt;/a&gt;. Follow us on Twitter &lt;a href= "https://twitter.com/HRheuminations"&gt;@Healio_OSN&lt;/a&gt;. You can find follow Trefoil Therapeutics on Twitter @TrefoilThera.&lt;/p&gt; &lt;p class="MsoNormal"&gt;&lt;strong&gt;David Eveleth, PhD,&lt;/strong&gt; is the president and CEO of Trefoil Therapeutics.&lt;/p&gt; &lt;p class="MsoNormal"&gt;&lt;strong&gt;Disclosures:&lt;/strong&gt; Eveleth is the founder, CEO and shareholder of Trefoil Therapeutics. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI.&lt;/p&gt;</description>

In this episode, I discuss corneal disease and treatments with David Eveleth, PhD, the founder, president and CEO of Trefoil Therapeutics. Brought to you by Alcon  ·       Welcome to another exciting episode of Eye Care...

Corneal Rejuvenation with Trefoil Therapeutics

In this episode, I chat with Nancy Lurker, CEO and board director, about EyePoint Pharmaceuticals and their latest treatments and trials. Brought to you by Alcon ·       Welcome to another exciting episode of Eye Care insider :13 ·       Intro Nancy Lurker :22 ·       Lurker’s background :58 ·       EyePoint Pharmaceuticals: the origin and transition 2:29 ·       Yutiq and long-acting drug delivery systems 6:07 ·       Additional indications for Yutiq 8:30 ·       What is the key factor in delivering this longer durability? 16:13 ·       Any consideration of looking at superiority of visual acuity and anatomical OCT gains? 21:47 ·       Is the primary focus wet AMD? Or are you also looking at NPDR and DME as potential indications? 24:19 ·       Investor information and neural protection data 29:01 ·       What is the most important issue that the field of ophthalmology is currently facing? 30:38 ·       Thanks for listening 32:37 We’d love to hear from you! Send your comments/questions to Dr. Mali at <a href= "mailto:eyecareinsider@healio.com">eyecareinsider@healio.com</a>. Follow us on Twitter <a href= "https://twitter.com/HRheuminations">@Healio_OSN</a>. You can find Nancy Lurker at @EyePointCEO and @EyePointPharma. Nancy Lurker is the board director and CEO of EyePoint Pharmaceuticals. Disclosures: Lurker is the board director and CEO of EyePoint Pharmaceuticals. Mali reports he is founder and CEO of Mali Enterprises; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI.

<description>&lt;p class="MsoNormal"&gt;In this episode, I chat with &lt;strong&gt;Nancy Lurker,&lt;/strong&gt; CEO and board director, about EyePoint Pharmaceuticals and their latest treatments and trials.&lt;/p&gt; &lt;p class="MsoNormal"&gt;&lt;em&gt;Brought to you by Alcon&lt;/em&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpFirst" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Welcome to another exciting episode of Eye Care insider &lt;strong&gt;&lt;em&gt;:13&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Intro Nancy Lurker &lt;strong&gt;&lt;em&gt;:22&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Lurker’s background &lt;strong&gt;&lt;em&gt;:58&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;EyePoint Pharmaceuticals: the origin and transition &lt;strong&gt;&lt;em&gt;2:29&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Yutiq and long-acting drug delivery systems &lt;strong&gt;&lt;em&gt;6:07&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Additional indications for Yutiq &lt;strong&gt;&lt;em&gt;8:30&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;What is the key factor in delivering this longer durability? &lt;strong&gt;&lt;em&gt;16:13&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Any consideration of looking at superiority of visual acuity and anatomical OCT gains? &lt;strong&gt;&lt;em&gt;21:47&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Is the primary focus wet AMD? Or are you also looking at NPDR and DME as potential indications? &lt;strong&gt;&lt;em&gt;24:19&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Investor information and neural protection data &lt;strong&gt;&lt;em&gt;29:01&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;What is the most important issue that the field of ophthalmology is currently facing? &lt;strong&gt;&lt;em&gt;30:38&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpLast" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Thanks for listening &lt;strong&gt;&lt;em&gt;32:37&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoNormal"&gt;We’d love to hear from you! Send your comments/questions to Dr. Mali at &lt;a href= "mailto:eyecareinsider@healio.com"&gt;eyecareinsider@healio.com&lt;/a&gt;. Follow us on Twitter &lt;a href= "https://twitter.com/HRheuminations"&gt;@Healio_OSN&lt;/a&gt;. You can find Nancy Lurker at @EyePointCEO and @EyePointPharma.&lt;/p&gt; &lt;p class="MsoNormal"&gt;&lt;strong&gt;Nancy Lurker&lt;/strong&gt; is the board director and CEO of EyePoint Pharmaceuticals.&lt;/p&gt; &lt;p class="MsoNormal"&gt;&lt;strong&gt;Disclosures:&lt;/strong&gt; Lurker is the board director and CEO of EyePoint Pharmaceuticals. Mali reports he is founder and CEO of Mali Enterprises; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI.&lt;/p&gt;</description>

In this episode, I chat with Nancy Lurker, CEO and board director, about EyePoint Pharmaceuticals and their latest treatments and trials. Brought to you by Alcon  ·       Welcome to another exciting episode of Eye Care...

EyePoint Pharmaceuticals’ EYP-1901: Promising Novel Drug Delivery System

In this episode, I discuss Samsara Vision’s SING IMT and its benefits of vision improvement for patients with AMD with Rebecca Kammer, OD, PhD. Brought to you by Alcon ·       Welcome to another exciting episode of Eye Care insider :14 ·       Intro for Rebecca Kammer, OD, PhD :27 ·       Dr. Kammer’s background 1:28 ·       Defining late-stage AMD patients and treatments available 5:11 ·       The SING IMT 9:46 ·       <a href= "https://www.oraconnects.com/find-a-trial-amd-old/">US Concerto Study Website</a> – to learn more about the study 13:13 ·       Visual acuity and the SING IMT 13:48 ·       US trial, recruitment and patient eligibility 17:18 ·       Contact toll-free 1-866-393-3767 discuss eligibility, participation and questions 20:39 ·       SING IMT as an option for patients 22:55 ·       Thanks for listening 27:30 We’d love to hear from you! Send your comments/questions to Dr. Mali at <a href= "mailto:eyecareinsider@healio.com">eyecareinsider@healio.com</a>. Follow us on Twitter <a href= "https://twitter.com/HRheuminations">@Healio_OSN</a>. You can reach Dr. Kammer at <a href= "mailto:rkammer@samsaravision.com">rkammer@samsaravision.com</a>. Rebecca Kammer, OD, PhD, is the vice president of worldwide clinical and medical affairs for Samsara Vision, Inc., an adjunct professor at University of California, Irvine and a diplomate in low vision of the American Academy of Optometry. Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI. Kammer reports being a clinical advisor to Biovisics and Eyedaptic.

<description>&lt;p class="MsoNormal"&gt;In this episode, I discuss Samsara Vision’s SING IMT and its benefits of vision improvement for patients with AMD with &lt;strong&gt;Rebecca Kammer, OD, PhD&lt;/strong&gt;.&lt;/p&gt; &lt;p class="MsoNormal"&gt;&lt;em&gt;Brought to you by Alcon&lt;/em&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpFirst" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Welcome to another exciting episode of Eye Care insider &lt;strong&gt;&lt;em&gt;:14&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Intro for Rebecca Kammer, OD, PhD &lt;strong&gt;&lt;em&gt;:27&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Dr. Kammer’s background &lt;strong&gt;&lt;em&gt;1:28&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Defining late-stage AMD patients and treatments available &lt;strong&gt;&lt;em&gt;5:11&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;The SING IMT &lt;strong&gt;&lt;em&gt;9:46&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;&lt;a href= "https://www.oraconnects.com/find-a-trial-amd-old/"&gt;US Concerto Study Website&lt;/a&gt; – to learn more about the study &lt;strong&gt;&lt;em&gt;13:13&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Visual acuity and the SING IMT &lt;strong&gt;&lt;em&gt;13:48&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;US trial, recruitment and patient eligibility &lt;strong&gt;&lt;em&gt;17:18&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Contact toll-free &lt;strong&gt;1-866-393-3767&lt;/strong&gt; discuss eligibility, participation and questions &lt;strong&gt;&lt;em&gt;20:39&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;SING IMT as an option for patients &lt;strong&gt;&lt;em&gt;22:55&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpLast" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Thanks for listening &lt;strong&gt;&lt;em&gt;27:30&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoNormal"&gt;We’d love to hear from you! Send your comments/questions to Dr. Mali at &lt;a href= "mailto:eyecareinsider@healio.com"&gt;eyecareinsider@healio.com&lt;/a&gt;. Follow us on Twitter &lt;a href= "https://twitter.com/HRheuminations"&gt;@Healio_OSN&lt;/a&gt;. You can reach Dr. Kammer at &lt;a href= "mailto:rkammer@samsaravision.com"&gt;rkammer@samsaravision.com&lt;/a&gt;.&lt;/p&gt; &lt;p class="MsoNormal"&gt;&lt;strong&gt;Rebecca Kammer, OD, PhD,&lt;/strong&gt; is the vice president of worldwide clinical and medical affairs for Samsara Vision, Inc., an adjunct professor at University of California, Irvine and a diplomate in low vision of the American Academy of Optometry.&lt;/p&gt; &lt;p class="MsoNormal"&gt;&lt;strong&gt;Disclosures:&lt;/strong&gt; Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI. Kammer reports being a clinical advisor to Biovisics and Eyedaptic.&lt;/p&gt;</description>

In this episode, I discuss Samsara Vision’s SING IMT and its benefits of vision improvement for patients with AMD with Rebecca Kammer, OD, PhD. Brought to you by Alcon  ·       Welcome to another exciting episode of...

Samsara Vision’s SING IMT: Game Changer for the Advanced AMD Patient

In this episode, I share my top five predictions for 2023 in the field of ophthalmology. Brought to you by Alcon <ul> <li>Welcome to another exciting episode of Eye Care insider :52</li> <li>My review of the top five predictions in ophthalmology 1:03</li> <li>Prediction #1 – Vabysmo and anti-VEGF market 1:53</li> <li>Prediction #2 – FDA approval for GA treatment 4:26</li> <li>Prediction #3 – <a href="http://www.snapseyeshield.com">SNAPS eye shield</a> for ocular protection 6:06</li> <li>Prediction #4 – biosimilars and the ophthalmic therapeutic marketplace 10:08</li> <li>Prediction #5 – retina analytical tools 12:27</li> <li>Thanks for listening 14:30</li> </ul> We’d love to hear from you! Send your comments/questions to Dr. Mali at <a href= "mailto:eyecareinsider@healio.com">eyecareinsider@healio.com</a>. Follow us on Twitter <a href= "https://twitter.com/HRheuminations">@Healio_OSN</a>. Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI.

<description>&lt;p&gt;In this episode, I share my top five predictions for 2023 in the field of ophthalmology.&lt;/p&gt; &lt;p&gt;&lt;em&gt;Brought to you by Alcon&lt;/em&gt;&lt;/p&gt; &lt;ul&gt; &lt;li&gt;Welcome to another exciting episode of Eye Care insider &lt;strong&gt;&lt;em&gt;:52&lt;/em&gt;&lt;/strong&gt;&lt;/li&gt; &lt;li&gt;My review of the top five predictions in ophthalmology &lt;strong&gt;&lt;em&gt;1:03&lt;/em&gt;&lt;/strong&gt;&lt;/li&gt; &lt;li&gt;Prediction #1 – Vabysmo and anti-VEGF market &lt;strong&gt;&lt;em&gt;1:53&lt;/em&gt;&lt;/strong&gt;&lt;/li&gt; &lt;li&gt;Prediction #2 – FDA approval for GA treatment &lt;strong&gt;&lt;em&gt;4:26&lt;/em&gt;&lt;/strong&gt;&lt;/li&gt; &lt;li&gt;Prediction #3 – &lt;a href="http://www.snapseyeshield.com"&gt;SNAPS eye shield&lt;/a&gt; for ocular protection &lt;strong&gt;&lt;em&gt;6:06&lt;/em&gt;&lt;/strong&gt;&lt;/li&gt; &lt;li&gt;Prediction #4 – biosimilars and the ophthalmic therapeutic marketplace &lt;strong&gt;&lt;em&gt;10:08&lt;/em&gt;&lt;/strong&gt;&lt;/li&gt; &lt;li&gt;Prediction #5 – retina analytical tools &lt;strong&gt;&lt;em&gt;12:27&lt;/em&gt;&lt;/strong&gt;&lt;/li&gt; &lt;li&gt;Thanks for listening &lt;strong&gt;&lt;em&gt;14:30&lt;/em&gt;&lt;/strong&gt;&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;We’d love to hear from you! Send your comments/questions to Dr. Mali at &lt;a href= "mailto:eyecareinsider@healio.com"&gt;eyecareinsider@healio.com&lt;/a&gt;. Follow us on Twitter &lt;a href= "https://twitter.com/HRheuminations"&gt;@Healio_OSN&lt;/a&gt;.&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Disclosures:&lt;/strong&gt; Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI.&lt;/p&gt;</description>

In this episode, I share my top five predictions for 2023 in the field of ophthalmology. Brought to you by Alcon  Welcome to another exciting episode of Eye Care insider :52 My review of the top five predictions in ophthalmology 1:03 Prediction #1 –...

Dr. Mali's Top 5 Predictions in Ophthalmology for 2023

In this episode, I share my thoughts about the five greatest innovations of the 21st century in the field of ophthalmology and how they have changed patient outcomes for the better. Brought to you by Alcon <ul> <li>Welcome to another exciting episode of Eye Care insider :50</li> <li>My review of the top five innovations in ophthalmology 1:02</li> <li>Greatest Innovation #1 – anti-VEGF medications 2:06</li> <li>Greatest Innovation #2 – intraocular lens implantation technology 3:26</li> <li>Greatest Innovation #3 – electronic medical records 4:08</li> <li>Greatest Innovation #4 – optical coherence tomography 5:48</li> <li>Greatest Innovation #5 – telemedicine 6:35</li> <li>Thanks for listening 7:44</li> </ul> We’d love to hear from you! Send your comments/questions to Dr. Mali at <a href= "mailto:eyecareinsider@healio.com">eyecareinsider@healio.com</a>. Follow us on Twitter <a href= "https://twitter.com/HRheuminations">@Healio_OSN</a>. Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular  Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.

<description>&lt;p&gt;In this episode, I share my thoughts about the five greatest innovations of the 21st century in the field of ophthalmology and how they have changed patient outcomes for the better.&lt;/p&gt; &lt;p&gt;&lt;em&gt;Brought to you by Alcon&lt;/em&gt;&lt;/p&gt; &lt;ul&gt; &lt;li&gt;Welcome to another exciting episode of Eye Care insider &lt;strong&gt;&lt;em&gt;:50&lt;/em&gt;&lt;/strong&gt;&lt;/li&gt; &lt;li&gt;My review of the top five innovations in ophthalmology &lt;strong&gt;&lt;em&gt;1:02&lt;/em&gt;&lt;/strong&gt;&lt;/li&gt; &lt;li&gt;Greatest Innovation #1 – anti-VEGF medications &lt;strong&gt;&lt;em&gt;2:06&lt;/em&gt;&lt;/strong&gt;&lt;/li&gt; &lt;li&gt;Greatest Innovation #2 – intraocular lens implantation technology &lt;strong&gt;&lt;em&gt;3:26&lt;/em&gt;&lt;/strong&gt;&lt;/li&gt; &lt;li&gt;Greatest Innovation #3 – electronic medical records &lt;strong&gt;&lt;em&gt;4:08&lt;/em&gt;&lt;/strong&gt;&lt;/li&gt; &lt;li&gt;Greatest Innovation #4 – optical coherence tomography &lt;strong&gt;&lt;em&gt;5:48&lt;/em&gt;&lt;/strong&gt;&lt;/li&gt; &lt;li&gt;Greatest Innovation #5 – telemedicine &lt;strong&gt;&lt;em&gt;6:35&lt;/em&gt;&lt;/strong&gt;&lt;/li&gt; &lt;li&gt;Thanks for listening &lt;strong&gt;&lt;em&gt;7:44&lt;/em&gt;&lt;/strong&gt;&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;We’d love to hear from you! Send your comments/questions to Dr. Mali at &lt;a href= "mailto:eyecareinsider@healio.com"&gt;eyecareinsider@healio.com&lt;/a&gt;. Follow us on Twitter &lt;a href= "https://twitter.com/HRheuminations"&gt;@Healio_OSN&lt;/a&gt;.&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Disclosures:&lt;/strong&gt; Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular  Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.&lt;/p&gt;</description>

In this episode, I share my thoughts about the five greatest innovations of the 21st century in the field of ophthalmology and how they have changed patient outcomes for the better. Brought to you by Alcon  Welcome to another exciting episode of Eye...

What Ophthalmologists Are Thankful For: Dr. Mali’s Top 5 Greatest Innovations Of The 21st Century in Ophthalmology

In this podcast, Joshua Mali, MD, brings you the best insights and perspectives in the field of eye care today. Through interviews with thought leaders in ophthalmology, Mali gets the inside of every story.

Eye Care Insider

Details

Recent Episodes